<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01439100</url>
  </required_header>
  <id_info>
    <org_study_id>OXN2504</org_study_id>
    <secondary_id>2011-002901-31</secondary_id>
    <nct_id>NCT01439100</nct_id>
  </id_info>
  <brief_title>A Randomised Placebo Controlled Study of OXN PR for Severe Parkinson's Disease Associated Pain</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mundipharma Research GmbH &amp; Co KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mundipharma Research GmbH &amp; Co KG</source>
  <brief_summary>
    <textblock>
      To demonstrate superiority of OXN PR compared to placebo with respect to analgesic efficacy&#xD;
      in subjects with chronic severe pain associated with Parkinson's disease (PD), as assessed by&#xD;
      averaged 24 hour pain scores collected for 7 days prior to the clinic visits&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pain management in PD is a recognised unmet need. Estimates of incidence vary in the&#xD;
      literature from 29% to 83%. The types and sources of pain experienced by PD patients vary and&#xD;
      include: musculoskeletal pain, PD related chronic pain, fluctuation-related pain, nocturnal&#xD;
      pain, coat-hanger pain, oro-facial pain and peripheral limb or abdominal pain (also including&#xD;
      drug-induced pain). Whilst modifications to dosing of dopaminergic therapy represents the&#xD;
      most common method of controlling some of these pain symptoms, this must be balanced against&#xD;
      the worsening of side effects of increased doses of this treatment type.&#xD;
&#xD;
      Oxycodone hydrochloride and naloxone hydrochloride dihydrate combined oral prolonged release&#xD;
      tablets (OXN PR), is the investigational product to be used in this study. OXN PR is a&#xD;
      prolonged release tablet consisting of oxycodone and naloxone in a 2:1 ratio. Due to the&#xD;
      local competitive antagonism of the opioid receptor-mediated oxycodone effect by naloxone in&#xD;
      the gut, naloxone reduces opioid-associated bowel dysfunction.&#xD;
&#xD;
      The purpose of this study is to investigate whether effective pain control for the treatment&#xD;
      of PD associated pain may be achieved with OXN PR. The secondary considerations for this&#xD;
      study are to examine whether OXN PR may offer any additional benefits to the patients Quality&#xD;
      of Life or symptoms of PD. If effective pain relief can be achieved with an analgesic without&#xD;
      the side effects described in above, this could reduce the need to increase the dose of&#xD;
      dopaminergic medications to manage pain, and therefore reduce the negative side effects of&#xD;
      dopaminergic therapy described above. Given the prevalence of constipation in this patient&#xD;
      population the bowel sparing effects of the OXN PR combination treatment may provide an&#xD;
      ethical rationale for its use over that of other opioids.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">172</enrollment>
  <condition>Parkinson's Disease With Severe Pain</condition>
  <arm_group>
    <arm_group_label>OXN PR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxycodone/Naloxone Prolonged Release tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dummy tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone/Naloxone Prolonged Release tablets</intervention_name>
    <arm_group_label>OXN PR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dummy tablet</description>
    <arm_group_label>Dummy tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Males and females, age of 25 years or over&#xD;
&#xD;
          2. Able to provide written informed consent&#xD;
&#xD;
          3. Primary diagnosis of Parkinson's disease Stage II-IV)&#xD;
&#xD;
          4. Graded as having severe pain&#xD;
&#xD;
          5. An average pain score of 6 or above on an 11 point NRS, over the previous 7 days&#xD;
&#xD;
          6. Female subjects willing to use an adequate and highly effective method of&#xD;
             contraception throughout the study.&#xD;
&#xD;
          7. Subjects likely to benefit from WHO step III opioid therapy for the duration of the&#xD;
             study&#xD;
&#xD;
          8. Subjects must not have received opioid containing medication in the last 6 months on a&#xD;
             regular basis&#xD;
&#xD;
          9. Receiving stable treatment for Parkinson's disease for at least 4 weeks prior to&#xD;
             randomisation&#xD;
&#xD;
         10. Subject does not have visual or auditory impairments that would reduce their ability&#xD;
             to complete study questionnaires or be unable to receive instructions for these&#xD;
&#xD;
         11. Concomitant medication (including co-analgesic) use anticipated to remain stable&#xD;
             throughout the Double-Blind Phase of the study&#xD;
&#xD;
         12. Subjects willing and able to participate in all aspects of the study and comply with&#xD;
             the use of study medication.&#xD;
&#xD;
        Open-Label Extension Inclusion Criteria&#xD;
&#xD;
        The aim of the Open-Label Phase is to ensure a safe transfer of all subjects to a&#xD;
        subsequent pain treatment after the study. Subjects must:&#xD;
&#xD;
          1. Still meet general inclusion criteria for Double-Blind Phase; subjects do not have to&#xD;
             meet inclusion 5, 6, 9 &amp; 12&#xD;
&#xD;
          2. Have completed the Double-Blind Phase or discontinued early but have had at least 8&#xD;
             weeks treatment with study medication.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Subjects who are to be excluded from the study are those who meet any of the following&#xD;
        criteria:&#xD;
&#xD;
        Medical Conditions&#xD;
&#xD;
          1. Cognitive impairment as assessed with the MMSE scoring 24 or less&#xD;
&#xD;
          2. History of psychosis (hallucinations, delusions, etc.)&#xD;
&#xD;
          3. History of drug or alcohol abuse or current compulsive addictive use of drugs or&#xD;
             alcohol&#xD;
&#xD;
          4. Parkinsonian-like disease secondary to drug therapy side-effects e.g. due to exposure&#xD;
             to medications that deplete dopamine (reserpine, tetrabenazine) or block dopamine&#xD;
             receptors (neuroleptics, antiemetics)&#xD;
&#xD;
          5. Parkinson-plus syndromes e.g. progressive supranuclear palsy (PSP) and the multiple&#xD;
             system atrophies (MSA)&#xD;
&#xD;
          6. Females who are pregnant (positive Î²-hCG test) or lactating&#xD;
&#xD;
          7. Any other contraindications to use of the opioid study medication(s) as per the&#xD;
             SmPC/IB:&#xD;
&#xD;
               -  Hypersensitivity to the active substances or to any of the excipients&#xD;
&#xD;
               -  Any situation where opioids are contraindicated&#xD;
&#xD;
               -  Severe respiratory depression with hypoxia and/or hypercapnia&#xD;
&#xD;
               -  Severe chronic obstructive pulmonary disease&#xD;
&#xD;
               -  Cor pulmonal&#xD;
&#xD;
               -  Severe bronchial asthma&#xD;
&#xD;
               -  Non-opioid induced paralytic ileus&#xD;
&#xD;
               -  Moderate to severe hepatic impairment (see exclusion criterion 16)&#xD;
&#xD;
          8. Any other contraindications to use of the study Double-Blind Phase rescue medication&#xD;
             as per the SmPC:&#xD;
&#xD;
               -  known hypersensitivity to levodopa or benserazide&#xD;
&#xD;
               -  contra-indicated in narrow-angle glaucoma (it may be used in wide-angle glaucoma&#xD;
                  provided that the intra-ocular pressure remains under control); severe&#xD;
                  psychoneuroses or psychoses; severe endocrine, renal, hepatic or cardiac&#xD;
                  disorders&#xD;
&#xD;
               -  should not be given in conjunction with, or within 2 weeks of withdrawal of,&#xD;
                  monoamine oxidase (MAO) inhibitors, except selective MAO-B inhibitors (e.g.&#xD;
                  selegiline) or selective MAO-A inhibitors (e.g. moclobemide) unless selective MAO&#xD;
                  inhibitors are given in combination in which case it is contraindicated&#xD;
&#xD;
               -  not be used in persons who have a history of, or who may be suffering from, a&#xD;
                  malignant melanoma&#xD;
&#xD;
          9. Subjects with any of the following as determined by medical history, clinical&#xD;
             laboratory tests, ECG results, and physical examination, that would place the subject&#xD;
             at risk upon exposure to the study medication:&#xD;
&#xD;
               -  myxoedema&#xD;
&#xD;
               -  untreated hypothyroidism&#xD;
&#xD;
               -  Addison's disease&#xD;
&#xD;
               -  increase of intracranial pressure&#xD;
&#xD;
               -  uncontrolled seizures or convulsive disorder&#xD;
&#xD;
               -  evidence of clinically significant cardiovascular, renal, hepatic,&#xD;
                  gastrointestinal (e.g. paralytic ileus), or psychiatric disease (subjects with&#xD;
                  controlled co-morbidities may be included following agreement with the Medical&#xD;
                  Monitor) Contraindicated Treatments&#xD;
&#xD;
         10. Treatment with Deep Brain Stimulation&#xD;
&#xD;
         11. Subjects receiving hypnotics or other central nervous system (CNS) depressants that,&#xD;
             in the Investigator's opinion, may pose a risk of additional CNS depression with&#xD;
             opioids study medication&#xD;
&#xD;
         12. Subjects presently taking, or who have taken, naloxone or naltrexone less than or&#xD;
             equal to 30 days prior to the Screening Visit&#xD;
&#xD;
         13. Subjects who have received an investigational medicinal product within 30 days of&#xD;
             study entry (defined as the start of the Screening Phase)&#xD;
&#xD;
         14. Any current use of an opioid other than the study medication provided&#xD;
&#xD;
         15. Subjects with a positive urine drug test at Screening Visit 1, which indicates&#xD;
             unreported illicit drug use or unreported use of a concomitant medication not required&#xD;
             to treat the Subjects' medical condition(s) Laboratory Exclusions&#xD;
&#xD;
         16. Abnormal parameters as defined:&#xD;
&#xD;
               -  aspartate aminotransferase (AST; SGOT) &gt; 3 times the upper limit of normal&#xD;
&#xD;
               -  alanine aminotransferase (ALT; SGPT) &gt; 3 times the upper limit of normal&#xD;
&#xD;
               -  alkaline phosphatase levels &gt; 3 times the upper limit of normal&#xD;
&#xD;
               -  gamma glutamyl transpeptidase (GGT or GGTP) &gt; 3 times the upper limit of normal&#xD;
&#xD;
               -  Abnormal total bilirubin and/or creatinine level(s) &gt; 1.5 times the upper limit&#xD;
                  of normal. Subjects whose total bilirubin levels or creatinine levels are below&#xD;
                  the lower limit of normal can participate in the study if they meet the criteria&#xD;
                  below:&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>FakultnÃ­ nemocnice u sv. Anny v BrnÄ NeurologickÃ¡ klinika</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poliklinika ChoceÅ NeuroligickÃ¡ ambulance</name>
      <address>
        <city>Chocen</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FakultnÃ­ nemocnice PlzeÅ NeurologickÃ¡ klinika</name>
      <address>
        <city>PlzeÅ-LochotÃ­n</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NeurologickÃ¡ ambulance</name>
      <address>
        <city>Policka</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CTC Rychnov nad KnÄÅ¾nou s.r.o.</name>
      <address>
        <city>Rychnov nad KnÄÅ¾nou</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologie Berlin</name>
      <address>
        <city>Berlin-Steglitz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruhr UniversitÃ¤t Bochum St. Josef-Hospital</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsmedizin GÃ¶ttingen Georg-August-UniversitÃ¤t</name>
      <address>
        <city>GÃ¶ttingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum fÃ¼r Altersmedizin</name>
      <address>
        <city>Haag i. OB</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paracelsus-Elena-Klinik</name>
      <address>
        <city>Kassel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philipps-UniversitÃ¤t</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Fachklinikum Abteilung fÃ¼r Neurologie</name>
      <address>
        <city>Stadtroda</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szent JÃ¡nos KÃ³rhÃ¡za Ã©s Ãszak-budai EgyesÃ­tett KÃ³rhÃ¡zaik</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KenÃ©zy KÃ³rhÃ¡z-RendelÅintÃ©zet EgÃ©szsÃ©gÃ¼gyi SzolgÃ¡ltatÃ³ Kft.</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szent Pantaleon KÃ³rhÃ¡z-RendelÅintÃ©zet DunaÃºjvÃ¡ros</name>
      <address>
        <city>DunaÃºjvÃ¡ros</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vaszary Kolos KÃ³rhÃ¡z Esztergom</name>
      <address>
        <city>Esztergom</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Petz AladÃ¡r Megyei OktatÃ³ KÃ³rhÃ¡z</name>
      <address>
        <city>GyÅr</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BÃ¡cs-Kiskun Megyei KÃ³rhÃ¡za</name>
      <address>
        <city>KecskemÃ©t</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Synapsa</name>
      <address>
        <city>Kielce</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krakowska Akademia Neurologii Sp. z o.o.</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Neuropsihiatrie</name>
      <address>
        <city>Craiova, Jud. Dolj</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital ClÃ­nic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USP Institut Universitari Dexeus</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universtario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Catalunya</name>
      <address>
        <city>Sant Cugat, Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairfield General Hospital Pennine Acute NHS Trust</name>
      <address>
        <city>Bury Great Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Preston Hospital</name>
      <address>
        <city>Preston</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City General Hospital, Pharmacy Dept, Newcastle Road</name>
      <address>
        <city>Stoke on Trent</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>September 21, 2011</study_first_submitted>
  <study_first_submitted_qc>September 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2011</study_first_posted>
  <last_update_submitted>February 5, 2014</last_update_submitted>
  <last_update_submitted_qc>February 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>severe pain</keyword>
  <keyword>OXN PR</keyword>
  <keyword>randomised</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

